Respiratory Distress Flashcards
Hypoxemia results from any combination of five mechanisms
Hypoventilation
Right-to-left shunt
Ventilation-perfusion (V ̇/Q ̇) mismatch
Diffusion impairment
Low inspired oxygen
occurs when blood enters the systemic circulation without traversing ventilated lung
Right-to-left shunt
A hallmark of significant right-to-left shunting is
the failure of arterial oxygen levels to increase in response to supplemental oxygen
increased A-a O2 gradient, and hypoxemia improves with supplemental oxygen
Ventilation-perfusion (V ̇/Q ̇) mismatch
Hypoxemia mechanism in
pulmonary emboli, pneumonia, asthma, chronic obstructive pulmonary disease, and even extrinsic vascular compression
Ventilation-perfusion (V ̇/Q ̇) mismatch
increased Paco2 and a normal A-a O2 gradient
Hypoventilation
A-a O2 gradient is increased, and hypoxemia improves with supplemental oxygen
Diffusion impairment
commonly seen at high altitude (including commercial air travel) or in nonobstructive asphyxia
Low inspired oxygen
True or false
Cyanosis, the blood or tissue discoloration associated with a lowered arterial oxygenation saturation, is not a sensitive or specific indicator of hypoxemia
True
True or false
Hypercapnia never results from increased CO2 production alone
True
Hypercapnia is exclusively caused by______________ and is defined as a Paco2_______ (>6 kPa)
alveolar hypoventilation
> 45 mm Hg
True or false
Do not withhold oxygen required to maintain minimum oxygen saturation levels in any chronic lung disease patient in an effort to stimulate ventilation and reduce hypercapnia
True
Acute cough is cough lasting ____________ and is usually associated with self-limited upper respiratory or bronchial infections
<3 weeks
Subacute cough lasts 3 to 8 weeks and is most commonly ___________
postinfectious
most common causes of chronic cough
(1) smoking, often with chronic bronchitis
(2) upper airway cough syndrome (formerly postnasal discharge)
(3) asthma
(4) gastroesophageal reflux
(5) angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker therapy